Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. (새로운 창 열기)

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Source‎: Ann Intern Med 2008;148(12):939-55.

Indexed‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 (새로운 창 열기)

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (새로운 창 열기)

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

Source‎: Am J Hematol 2000;64(1):26-31.

Indexed‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 (새로운 창 열기)

Hydroxyurea for the treatment of sickle cell anemia. (새로운 창 열기)

Platt OS.

Source‎: N Engl J Med 2008;358(13):1362-9.

Indexed‎: PubMed 18367739

DOI‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 (새로운 창 열기)

Clinical effectiveness of decitabine in severe sickle cell disease. (새로운 창 열기)

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

Source‎: Br J Haematol 2008;141(1):126-9.

Indexed‎: PubMed 18324975

DOI‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 (새로운 창 열기)

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (새로운 창 열기)

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Source‎: Blood 2010;115(12):2354-63.

Indexed‎: PubMed 19903897

DOI‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 (새로운 창 열기)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (새로운 창 열기)

Hirst C, Owusu-Ofori S.

Source‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Indexed‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (새로운 창 열기)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (새로운 창 열기)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Source‎: Lancet Haematol 2021;8(5):e323-33.

Indexed‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (새로운 창 열기)

Sickle cell disease. (새로운 창 열기)

Meremikwu MM, Okomo U.

Source‎: BMJ Clin Evid 2011;02:2402.

Indexed‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (새로운 창 열기)

A phase 3 trial of l-glutamine in sickle cell disease. (새로운 창 열기)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Source‎: N Engl J Med 2018;379(3):226-35.

Indexed‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (새로운 창 열기)

Malaria chemoprophylaxis in sickle cell disease. (새로운 창 열기)

Oniyangi O, Omari AA.

Source‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Indexed‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (새로운 창 열기)